Irena Oblak

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Jesse J. Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson et al. · The Lancet · 2023 · 514 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study

Vaneja Velenik, Janja Ocvirk, Maja Marolt Mušič et al. · Radiation Oncology · 2011 · 88 citations · Full text

Medicine, Oncology, Surgery +17

Impact of COVID-19 on cancer diagnosis and management in Slovenia – preliminary results

Vesna Zadnik, Ana Mihor, Sonja Tomšič et al. · Radiology and Oncology · 2020 · 85 citations · Full text

Medicine, Oncology, Cancer Control +15

Postoperative concomitant irradiation and chemotherapy with mitomycin C and bleomycin for advanced head-and-neck carcinoma

Lojze Šmid, Marjan Budihna, Branko Zakotnik et al. · International Journal of Radiation Oncology*Biology*Physics · 2003 · 58 citations

Medicine, Oncology, Surgery +9

A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer

Vaneja Velenik, Janja Ocvirk, Irena Oblak et al. · European Journal of Surgical Oncology · 2009 · 53 citations · Full text

Medicine, Oncology, Surgery +16